

# The Use of Cannabidiol in Treatment Resistant Epilepsy: A Literature Review of the Efficacy of CBD in Dravet Syndrome

Author: Holly Stockhover Faculty Mentor: Dr. Cheryl Crisp  
University Affiliation: IUPUC Sponsor: Office of Student Research

This report presents a review of the literature supporting the efficacy of CBD in treating children and adolescents with forms of treatment resistant epilepsy (TRE) such as Dravet Syndrome (DS)

## Methods

- Literature search conducted between December 2016 and January 2017
- Databases used: Google Scholar, PubMed, and CINAHL
- Key search terms used to generate highest number of results
- Results refined to articles from 2013 – 2017
- Abstracts reviewed to find articles fitting inclusion criteria



## Results

Study Type	# Participants	Some Reduction	> 50% Reduction	>75% Reduction	Remission	Non-Seizure Benefits	Worsening Seizures	Mild AEs	SAEs
Retrospective	119	58	24	0	0	63	10	23	0
Retrospective	74	66	25	13	0	NR	5	NR	NR
Parental Report	19	NR	NR	5	0	NR	0	NR	NR
Parental Report	19	16	3	0	0	15	0	3	0
Dosing & Remission 1A	1	1	N/A	N/A	1	Y	N	NR	0
Dosing & Remission 1B	1	1	N/A	N/A	1	Y	N	NR	0
Dosing & Remission 2	1	1	N/A	N/A	1	Y	N	NR	0
Experimental 1	137	137	137	0	12	NR	10	>10%	52
Experimental 2A	27	27	13	6	2	NR	0	Y	0
Experimental 2B	9	9	5	3	2	NR	0	Y	0

NR= Not Recorded  
N/A= Not applicable  
Y= Yes  
N=No

## Conclusion

There is still much to be done before medicinal marijuana can be considered a first-line treatment for epilepsy, but current literature and studies are paving the way for future legislation. Although further research is still required on this topic, this literature review has provided strong evidence suggesting the efficacy of CBD therapies in children and adolescents with TRE such as DS.

## References

- Babayeva, M., Fuzailov, M., Rozenfeld, P., & Basu, P. (2014). Marijuana compounds: a nonconventional therapeutic approach to epilepsy in children. *Addiction and Neuropharmacology*, 1(1), 1 – 9. Retrieved from [https://www.researchgate.net/profile/Mariana\\_Babayeva2/publication/271443312\\_Marijuana\\_Compounds\\_A\\_NonConventional\\_Therapeutic\\_Approach\\_to\\_Epilepsy\\_in\\_Children/links/551c13e80e2909047b9c14d.pdf](https://www.researchgate.net/profile/Mariana_Babayeva2/publication/271443312_Marijuana_Compounds_A_NonConventional_Therapeutic_Approach_to_Epilepsy_in_Children/links/551c13e80e2909047b9c14d.pdf)
- Crippa, J. A. S., Crippa, A. C. S., Hallak, J. E. C., Martin-Santos, R. (2016). Δ9-THC intoxication by cannabidiol-enriched cannabis extract in two children with refractory epilepsy: full remission after switching to purified cannabidiol. *Frontiers in Pharmacology*, 7(359), 1 – 6. doi: 10.3389/fphar.2016.00359
- Devinsky, O., Cilio, M. R., Cross, H., Fernandez-Ruiz, J., French, J., Hill, C., ... Friedman, D. (2014). Cannabidiol: pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders. *Epilepsia*, 55(6), 791 – 802. doi: 10.1111/epi.12631
- Devinsky, O., Sullivan, J., Friedman, D., Thiele, E., Marsh, E., Laux, L., ... Cilio, M. R. (n.d.). *Epidiolex (cannabidiol) in treatment resistant epilepsy*. Retrieved from <https://pdfs.semanticscholar.org/bef/4ac8b68b028b7b07a1e1f4252b58afca4a7.pdf>
- Guy, G., Wright, S., Mead, A., Joshi, C., & Wilfong, A. (2015). Use of cannabinoids in the treatment of epilepsy. Retrieved from <https://www.google.com/patents/US20150359755>
- Maa, E., & Figi, P. (2014). The case for medical marijuana in epilepsy. *Epilepsia*, 55(6), 783 – 786. doi: 10.1111/epi.12610
- Porter, B. E., & Jacobson, C. (2013). Report of a parent survey of cannabidiol-enriched cannabis use in pediatric treatment-resistant epilepsy. *Epilepsy & Behavior*, 29, 574 – 577. doi: 10.1016/j.yebeh.2013.08.037
- Press, C. A., Knupp, K. G., & Chapman, K.E. (2015). Parental reporting of response to oral cannabis extracts for treatment of refractory epilepsy. *Epilepsy and Behavior*, 45, 49 – 52. doi: 10.1016/j.yebeh.2015.02.043
- Treat, L., Chapman, K. E., Colborn, K. L., & Knupp, K. G. (2016). Duration of use of oral cannabis extract in a cohort of pediatric epilepsy patients. *Epilepsia*, 58(1), 123 – 127. doi: 10.1111/epi.13617
- Tzadok, M., Ulriel-Siboni, S., Linder, I., Kramer, U., Epstein, O., Menascu, I., ... & Ben-Zeev, B. (2016). CBD-enriched medical cannabis for intractable pediatric epilepsy: the current Israeli experience. *Seizure*, 35, 41 – 44. doi: 10.1016/j.seizure.2016.01.004
- Welty, T. E., Luebke, A., & Gidal, B. E. (2014). Cannabidiol: promise and pitfalls. *Epilepsy Currents*, 14(5), 250 – 252. Retrieved from <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4189631/pdf/i1535-7511-14-5-250.pdf>